What is the intrinsic value of BLFS?
As of 2026-09-15, the Intrinsic Value of BioLife Solutions Inc (BLFS) is
5.93 USD. This BLFS valuation is based on the model Peter Lynch Fair Value.
With the current market price of 36.39 USD, the upside of BioLife Solutions Inc is
-83.72%.
Is BLFS undervalued or overvalued?
Based on its market price of 36.39 USD and our intrinsic valuation, BioLife Solutions Inc (BLFS) is overvalued by 83.72%.
BLFS Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
(20.74) - (4.33) |
(7.15) |
-119.6% |
| DCF (Growth 10y) |
(5.10) - (22.62) |
(8.14) |
-122.4% |
| DCF (EBITDA 5y) |
(0.37) - (0.06) |
(1,234.50) |
-123450.0% |
| DCF (EBITDA 10y) |
(1.02) - (0.17) |
(1,234.50) |
-123450.0% |
| Fair Value |
5.93 - 5.93 |
5.93 |
-83.72% |
| P/E |
29.84 - 34.99 |
32.59 |
-10.4% |
| EV/EBITDA |
3.02 - 4.59 |
3.43 |
-90.6% |
| EPV |
3.81 - 5.57 |
4.69 |
-87.1% |
| DDM - Stable |
12.12 - 75.08 |
43.60 |
19.8% |
| DDM - Multi |
(1.73) - (8.54) |
(2.90) |
-108.0% |
BLFS Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
1,780.20 |
| Beta |
0.83 |
| Outstanding shares (mil) |
48.92 |
| Enterprise Value (mil) |
1,756.20 |
| Market risk premium |
4.60% |
| Cost of Equity |
8.13% |
| Cost of Debt |
5.71% |
| WACC |
8.13% |